Title: Construction of a novel signature based on immune-related lncRNA to identify high and
low risk pancreatic adenocarcinoma patients
Version: 1 Date: 29 Apr 2023
Reviewer's report:
Very interesting and well conducted study. I don't have major concerns.
My only comments is on the need of a stronger validation of these results. How the authors think
to confirm their results through a validation approach?
The authors should comment in the Discussion on the need of good quality samples in the clinical
practice of these patients, for example by means of Endoscopic ultrasound FNB (in this regard
cite the recent papers PMID: 35124072  and PMID: 35915956)
Title: Construction of a novel signature based on immune-related lncRNA to identify high and
low risk pancreatic adenocarcinoma patients
Version: 1 Date: 29 Apr 2023
Reviewer's report:
Very interesting and well conducted study. I don't have major concerns.
My only comments is on the need of a stronger validation of these results. How the authors think
to confirm their results through a validation approach?
The authors should comment in the Discussion on the need of good quality samples in the clinical
practice of these patients, for example by means of Endoscopic ultrasound FNB (in this regard
cite the recent papers PMID: 35124072  and PMID: 35915956)
Please review this paper.
user
Title: Construction of a novel signature based on immune-related lncRNA to identify high and
low risk pancreatic adenocarcinoma patients
Version: 1 Date: 29 Apr 2023
Reviewer's report:
Very interesting and well conducted study. I don't have major concerns.
My only comments is on the need of a stronger validation of these results. How the authors think
to confirm their results through a validation approach?
The authors should comment in the Discussion on the need of good quality samples in the clinical
practice of these patients, for example by means of Endoscopic ultrasound FNB (in this regard
cite the recent papers PMID: 35124072  and PMID: 35915956)
assistant